Page 3 of 5: studies 41 to 60 of 97, newest first. Back to the MDMA overview
Psychopharmacology July 20, 2010
Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats.
Journal of Psychopharmacology July 19, 2010 Michael C Mithoefer, Mark T Wagner, Ann T Mithoefer et al. 672 citations
Case reports indicate that psychiatrists administered ±3,4-methylenedioxymethamphetamine (MDMA) as a catalyst to psychotherapy before recreational use of MDMA as 'Ecstasy' resulted in its criminalization in 1985. Over two decades later, this study is the first completed clinical trial evaluating MDMA as a therapeutic adjunct. Twenty patients with chronic posttraumatic stress disorder,...
Journal of Pharmacology and Experimental Therapeutics July 16, 2010 Bethann N. Johnson, Bryan K. Yamamoto 22 citations
Stress facilitates drug abuse by humans. In rodents, stress enhances the neurochemical, neuroendocrine, and behavioral responses to psychostimulants. Although chronic unpredictable stress (CUS) enhances the acute hyperthermic and long-term monoamine-depleting effects of the psychostimulant +3,4-methylenedioxymethamphetamine (MDMA), the roles of hyperthermia and corticosterone (CORT) in...
European Journal of Pharmacology July 13, 2010
Role of serotonin and/or norepinephrine in the MDMA-induced increase in extracellular glucose and glycogenolysis in the rat brain.
Developmental Neuroscience July 10, 2010
Neurotoxic effects of MDMA (ecstasy) on the developing rodent brain.
Journal of Psychopharmacology July 8, 2010
Procedural and declarative memory task performance, and the memory consolidation function of sleep, in recent and abstinent ecstasy/MDMA users.
Addiction Biology July 2010 Francesco Angelucci, Valerio Ricci, Giovanni Martinotti et al.
The recreational drug 'ecstasy'[3,4-methylenedioxymethamphetamine (MDMA)] exerts a potent action on central serotonergic and dopaminergic neurons. These neurons utilize neurotrophins for their survival and function. In order to explore MDMA effects on neurotrophins, we measured by enzyme-linked immunosorbent assay the serum levels of brain-derived neurotrophic factor (BDNF) and nerve growth...
Current Pharmaceutical Biotechnology June 27, 2010 Emanuela Turillazzi, Irene Riezzo, Margherita Neri et al. 43 citations
Studies conducted in humans or in animals explored the presence, nature and potential causes of 3,4-methylenedioxymethamphetamine (MDMA) toxicity. According to literature, there are four principal types of such serious toxicity: hepatic, cardiovascular, cerebral and hyperpyrexic. The molecular mechanisms involved in the genesis of these toxic effects are not yet fully clarified, but the...
Current Pharmaceutical Biotechnology June 27, 2010 Byoung‐joon Song, Kwan–hoon Moon, Vijay Upreti et al. 73 citations
Despite numerous reports about the acute and sub-chronic toxicities caused by MDMA (3,4-methylenedioxymethamphetamine, ecstasy), the underlying mechanism of organ damage is poorly understood. The aim of this review is to present an update of the mechanistic studies on MDMA-mediated organ damage partly caused by increased oxidative/nitrosative stress. Because of the extensive reviews on...
Current Pharmaceutical Biotechnology June 27, 2010 Sumit Sarkar, Larry Schmued 63 citations
"Ecstasy" (MDMA) is a powerful hallucinogenic drug which has raised concern worldwide because of its high abuse liability. A plethora of studies have demonstrated that MDMA has the potential to induce neurotoxicity both in human and laboratory animals. Although research on MDMA has been carried out by many different laboratories, the mechanism underlying MDMA induced toxicity has not been fully...
Toxicology in Vitro June 2010 Rokhsareh Meamar, Fereshteh Karamali, Hamid Mirmohamad Sadeghi et al.
"Ecstasy" or methylenedioxymethamphetamine (MDMA) is primarily a recreational drug commonly used during the child bearing period, thus, there is a major concern regarding the embryonic and fetal toxicity of this drug. Here, we report the cardio- and neuro-toxic effects of MDMA on beating embryoid bodies (EBs) and neural cell-containing EBs derived from mouse embryonic stem cell (ESCs). Based on...
Synapse June 1, 2010
Repeated intermittent methylenedioxymethamphetamine exposure protects against the behavioral and neurotoxic, but not hyperthermic, effects of an MDMA binge in adult rats.
British Journal of Pharmacology May 27, 2010 Noreen T. Boyle, Thomas J. Connor 42 citations
Methylenedioxymethamphetamine (MDMA; 'Ecstasy') is a ring-substituted amphetamine and a popular drug of abuse. In addition to ability to induce euphoria, MDMA abuse is associated with a range of acute and long-term hazardous effects. This paper is focused on once such adverse effect: its ability to negatively impact on functioning of the immune system. Research demonstrates that MDMA has...
British Journal of Pharmacology May 24, 2010 Natacha Vanattou‐saïfoudine, Ruth Mcnamara, Andrew Harkin 39 citations
Background and purpose: Caffeine exacerbates the hyperthermia associated with an acute exposure to 3,4 methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) in rats. The present study investigated the mechanisms mediating this interaction. Experimental approach: Adult male Sprague‐Dawley rats were treated with caffeine (10 mg·kg −1 ; i.p.) and MDMA (15 mg·kg −1 ; i.p.) alone and in combination. Core...
Human & Experimental Toxicology May 20, 2010 Pinchas Halpern, Jenny Moskovich, Beni Avrahami et al. 54 citations
Methods: We conducted a prospective, representative-sample nationwide study on morbidity related to 3,4, methylenedioxymethamphetamine (MDMA; ‘ecstasy’) as determined from admissions to 5 geographically representative emergency departments (EDs) and from data from the poison information center (PIC). MDMArelated ED admissions were analyzed over a 7-month period and the records of all PIC calls...
Journal of Pharmacological Sciences May 19, 2010
Sustained exposure to 3,4-methylenedioxymethamphetamine induces the augmentation of exocytotic serotonin release in rat organotypic raphe slice cultures.
Brain May 17, 2010 Stephen J. Kish, Jason P. Lerch, Yoshiaki Furukawa et al. 170 citations
Animal data indicate that the recreational drug ecstasy (3,4-methylenedioxymethamphetamine) can damage brain serotonin neurons. However, human neuroimaging measurements of serotonin transporter binding, a serotonin neuron marker, remain contradictory, especially regarding brain areas affected; and the possibility that structural brain differences might account for serotonin transporter binding...
Journal of Neuroscience Research May 15, 2010 Eva L Van Donkelaar, Paul A. Kelly, Neil Dawson et al.
The serotonergic (5-hydroxytryptamine; 5-HT) dysfunction found in depression may affect not only brain function (mood) but also cerebrovascular control. Similar, but possibly occult, disturbances may also be induced by 3,4-methylenedioxymethamphetamine-induced neurotoxicity (MDMA, or "ecstasy"). Acute tryptophan depletion (ATD) is widely used to identify vulnerability to depression, and we...
Journal of Pharmacology and Experimental Therapeutics May 13, 2010
Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys.
Addiction Biology May 11, 2010
Tolerance to 3,4-methylenedioxymethamphetamine is associated with impaired serotonin release.